GlassScriptPhysician profile
David J Harnick
NPI 1942212642
$168,886.98
in general payments reported to CMS, 2019-2025
43 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $28K · 2021: $48K · 2022: $50K · 2023: $9,018 · 2024: $7,511 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,859 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,384 · Consulting Fee: $4,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,858.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,383.50 |
| Consulting Fee | $4,966.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $105,670.37 | 2019-2024 | |
| Biotronik INC. | $20,583.03 | 2019-2025 | Biomonitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,482.95 | 2019-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $4,158.40 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $3,500.00 | 2019 | |
| Medtronic Vascular, INC. | $3,203.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $2,067.77 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $1,753.64 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $1,465.43 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Abbott Laboratories | $1,413.33 | 2019-2023 | Mitraclip |
| Esperion Therapeutics, INC. | $1,404.53 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $1,388.46 | 2019-2025 | |
| Medtronic, INC. | $1,266.48 | 2021-2025 | Mycarelink, Linq II, Corevalve Evolut R |
| Amgen INC. | $803.00 | 2019-2025 | Repatha |
| Novo Nordisk INC | $721.12 | 2019-2025 | Wegovy |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $705.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $610.39 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $560.87 | 2019-2024 | Livalo |
| Merck Sharp & Dohme LLC | $535.40 | 2021-2025 | Verquvo, Capvaxive |
| Amarin Pharma, INC. | $409.86 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $376.65 | 2019-2025 | Eliquis, Camzyos |
| Elutia, INC. | $350.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $301.85 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $286.21 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $281.00 | 2020-2025 | Amvuttra, Onpattro |
| Lundbeck LLC | $248.02 | 2019-2021 | |
| Vifor Pharma, INC. | $231.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $198.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $170.46 | 2019 | |
| Bridgebio Pharma, INC. | $153.52 | 2025 | Attruby |
| G Medical Diagnostic Services, INC. | $114.70 | 2019-2022 | |
| Medicomp INC | $88.78 | 2025 | Telepatch Cardiac Monitor |
| Akcea Therapeutics, INC. | $81.80 | 2020 | |
| Bardy Diagnostics, INC. | $50.82 | 2021-2022 | |
| Corcept Therapeutics | $50.43 | 2025 | Korlym |
| Impulse Dynamics (USA) INC. | $36.37 | 2025 | Optimizer |
| Inspire Medical Systems, INC. | $36.14 | 2023 | Inspire |
| Agepha Pharma Fz LLC | $27.40 | 2025 | Lodoco |
| Heartflow, INC. | $22.63 | 2025 | |
| Abbvie INC. | $20.57 | 2021 | |
| Astellas Pharma US INC | $19.51 | 2019 | |
| Althera Pharmaceuticals LLC | $18.78 | 2021 | |
| Philips North America LLC | $16.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Harnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.